Overview
This is a phase Ib, open-label, dose-validating and safety study of caffeine in neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia.
Description
In a previous phase I trial (NCT03913221), the investigators characterized the pharmacokinetics (PK) of caffeine in the setting of HIE and therapeutic hypothermia using a population PK model. This is an open-label study of caffeine citrate in neonates with HIE to validate the population PK model and determine optimal dosing for HIE.
Eligibility
Inclusion Criteria:
- Documented informed consent from parent or guardian
- ≥ 36 weeks gestational age at birth
- Receiving therapeutic hypothermia for a diagnosis of HIE
- Intravenous (IV) access
- Postnatal age < 24 hours
Exclusion Criteria:
- Receiving > 1 anti-epileptic drug for seizures
- Sustained (>4 hours) heart rate > 180 beats per minute
- Known major congenital anomaly